Drug discontinuation: Mirikizumab-mrkz Injection (OMVOH)
FDA lists 2 presentations as To Be Discontinued. Companies: Eli Lilly and Co..
- Published by source
- 2025-12-22
- First seen by Reality Radar
- 2026-10-22
- Last verified
- 2026-10-22
Affected
- Manufacturer
- Eli Lilly and Co.
- Products
- Mirikizumab-mrkz Injection OMVOH
Whether your exact unit is affected depends on the model, serial number and region in the official notice.
What the official notice says
Risk: To Be Discontinued
Remedy / actions:
- A business decision was made to discontinue. Distribution will end April 2026. The 200 mg/2 mL injection presentation (NDC 0002-1442-11) will remain.
- A business decision was made to discontinue. Distribution will end April 2026. The 200 mg/2 mL injection presentation (NDC 0002-3116-11) will remain.
Is this affecting you?
Add what you own or use and Reality Radar will tell you when official changes match it — with evidence and next steps.
Sources
- openFDA Drug Shortages Tier A · official published 2025-12-22
Evidence ledger
Every piece of evidence we store is appended to a public hash chain, so later edits are detectable. Anyone can re-verify it.
| Entry | Kind | Observed | Evidence hash | Entry hash |
|---|---|---|---|---|
| #1021 | new | 2026-10-22 | ce1143e41bba…509fd1 | 0f4b99462251…96d385 |
Chain head: #1094 edf3be25ec2e…478842